1. Home
  2. AAT vs IMCR Comparison

AAT vs IMCR Comparison

Compare AAT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Assets Trust Inc.

AAT

American Assets Trust Inc.

HOLD

Current Price

$25.31

Market Cap

1.5B

Sector

Real Estate

ML Signal

HOLD

IMCR

Immunocore Holdings plc

HOLD

Current Price

$32.53

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAT
IMCR
Founded
1967
2008
Country
United States
United Kingdom
Employees
208
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
AAT
IMCR
Price
$25.31
$32.53
Analyst Decision
Sell
Buy
Analyst Count
2
10
Target Price
$19.50
$66.33
AVG Volume (30 Days)
455.3K
548.6K
Earning Date
04-28-2026
05-07-2026
Dividend Yield
6.65%
N/A
EPS Growth
N/A
30.39
EPS
0.08
0.25
Revenue
$436,204,000.00
$249,428,000.00
Revenue This Year
$4.33
$14.57
Revenue Next Year
$0.22
$8.21
P/E Ratio
$315.25
$126.60
Revenue Growth
N/A
43.05
52 Week Low
$17.72
$27.56
52 Week High
$25.34
$40.71

Technical Indicators

Market Signals
Indicator
AAT
IMCR
Relative Strength Index (RSI) 70.84 69.39
Support Level $18.23 $31.02
Resistance Level N/A $33.32
Average True Range (ATR) 0.49 1.14
MACD -0.02 0.40
Stochastic Oscillator 88.95 95.79

Price Performance

Historical Comparison
AAT
IMCR

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: